Evidence map›Paper›PMID 42705663›Full record

ArticleBMJ open2026

Pragmatic randomised controlled trial to evaluate the clinical and cost-effectiveness of compression therapy for surgical wounds healing by secondary intention following excision of lower limb keratinocyte cancers in UK skin cancer surgery centres (HEALS2 trial): study protocol.

Henrietta Konwea, Myka Ransom, Rachel Abbott, Iqra Ashraf, Chris Bojke, Sarah Tess Brown, Howard Collier, Joanna Connor, Rachael Mary Gilberts, Jasmine Mann and 6 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Henrietta KonweaAcademic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK i.h.konwea@leeds.ac.uk.ORCID 0009-0004-8058-9640
Myka RansomLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID 0000-0003-4359-8287
Rachel AbbottUniversity Hospital of Wales Healthcare NHS Trust, Cardiff, Wales, UK.ORCID 0000-0002-3415-7132
Iqra AshrafSouth Warwickshire University NHS Foundation Trust, Warwick, UK.
Chris BojkeAcademic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.ORCID 0000-0003-2601-0314
Sarah Tess BrownLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID 0000-0002-1840-3786
Howard CollierLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID 0000-0002-0107-0604
Joanna ConnorLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID 0009-0009-1592-3119
Rachael Mary GilbertsLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID 0000-0003-3326-7900
Jasmine MannHomerton Healthcare NHS Foundation Trust, London, UK.
Annah MuliLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Jane NixonLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Emma PynnAneurin Bevan University Health Board, Abergavenny, Wales, UK.ORCID 0000-0001-9829-1165
David VeitchDepartment of Dermatology, St Michael's Clinic, Shrewsbury, UK.
A G H WernhamDepartment of Dermatology, Royal Wolverhampton NHS Trust, Wolverhampton, UK.ORCID 0000-0001-5920-6888
Elizabeth McGinnisLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.ORCID 0000-0002-2848-9149

Funding

UK NIHR and the Department of Health and Social Care NIHR151863
6 · The paper itself

Abstract

introductionKeratinocyte cancers (KCs) are increasing in incidence in the UK, with over 234 000 cases annually, largely due to demographic changes and sun exposure. Skin cancers, including malignant melanoma and KCs, are projected to cost the NHS over £180 million annually and impose healthcare demands. Although KCs have high cure rates following surgical excision and primary closure, wounds healing by secondary intention (HBSI) particularly on the lower leg present clinical challenges. Compression therapy (CT) known to improve venous insufficiency and venous ulcer healing may also benefit HBSI following lower limb KC excision but current evidence is sparse. METHODS AND ANALYSIS: ETHICS AND DISSEMINATION: Ethics approval has been granted by the Yorkshire & The Humber - Leeds East Research Ethics Committee (ref 23/YH/0247). Findings will be published in high-impact peer-reviewed journals. TRIAL REGISTRATION NUMBER: ISRCTN12417689.

Indexed as

Compression BandagesSkin NeoplasmsSurgical WoundWound HealingClinical Trials, Phase III as TopicCost-Benefit AnalysisCost-Effectiveness AnalysisHumansKeratinocytesLower ExtremityMulticenter Studies as TopicPragmatic Clinical Trials as TopicProspective StudiesQuality of LifeRandomized Controlled Trials as TopicUnited KingdomDermatological tumoursSurgical dermatologyWOUND MANAGEMENT

Identifiers

PMID42705663
PMCPMC13560984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.